227 related articles for article (PubMed ID: 22583164)
21. Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.
Chen YT; Ying YH; Chang K; Hsieh YH
Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 26938547
[TBL] [Abstract][Full Text] [Related]
22. Willingness to pay and quality of life in patients with pruritic skin disorders.
Stefanidou M; Evangelou G; Kontodimopoulos N; Koumaki D; Krueger-Krasagakis SE; Yosipovitch G; Krasagakis K
Arch Dermatol Res; 2019 Apr; 311(3):221-230. PubMed ID: 30788568
[TBL] [Abstract][Full Text] [Related]
23. An assessment of the burden of migraine using the willingness to pay model.
Hamelsky SW; Lipton RB; Stewart WF
Cephalalgia; 2005 Feb; 25(2):87-100. PubMed ID: 15658945
[TBL] [Abstract][Full Text] [Related]
24. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life.
Holme SA; Anstey AV; Finlay AY; Elder GH; Badminton MN
Br J Dermatol; 2006 Sep; 155(3):574-81. PubMed ID: 16911284
[TBL] [Abstract][Full Text] [Related]
25. Willingness to pay to assess patient preferences for therapy in a Canadian setting.
Marra CA; Frighetto L; Goodfellow AF; Wai AO; Chase ML; Nicol RE; Leong CA; Tomlinson S; Ferreira BM; Jewesson PJ
BMC Health Serv Res; 2005 Jun; 5():43. PubMed ID: 15941474
[TBL] [Abstract][Full Text] [Related]
26. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
Franic DM; Bothe AK; Bramlett RE
J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses.
Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Vallet C; Mère A; Labetoulle G; Le Fol C; Dréno B
Dermatology; 2012; 224(4):374-80. PubMed ID: 22759904
[TBL] [Abstract][Full Text] [Related]
28. Assessing the value of symptom relief for patients with gastroesophageal reflux disease treatment: willingness to pay using a discrete choice experiment.
Deal K; Marshall D; Dabrowski D; Charter A; Bukoski M; Moayyedi P
Value Health; 2013 Jun; 16(4):588-98. PubMed ID: 23796293
[TBL] [Abstract][Full Text] [Related]
29. Willingness to pay for potential enhancements to a low-cost cataract surgical package in rural southern China.
Ko F; Frick KD; Tzu J; He M; Congdon N
Acta Ophthalmol; 2012 Feb; 90(1):e54-60. PubMed ID: 21801337
[TBL] [Abstract][Full Text] [Related]
30. Impact of Vitiligo on Life Quality of Patients: Assessment of Currently Available Tools.
Yang TT; Lee CH; Lan CE
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429664
[TBL] [Abstract][Full Text] [Related]
31. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
32. Quality of health care of rosacea in Germany from the patient's perspective: results of the national health care study Rosareal 2009.
Langenbruch AK; Beket E; Augustin M
Dermatology; 2011; 223(2):124-30. PubMed ID: 21893958
[TBL] [Abstract][Full Text] [Related]
33. Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
[TBL] [Abstract][Full Text] [Related]
34. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea.
Baldwin HE
Cutis; 2010 Nov; 86(5 Suppl):26-36. PubMed ID: 21229828
[TBL] [Abstract][Full Text] [Related]
35. Willingness to pay for a cure of low-risk melanoma patients in Germany.
Augustin M; Blome C; Forschner A; Gutzmer R; Hauschild A; Heinzerling L; Livingstone E; Loquai C; Schadendorf D; Utikal J; Wagner T; Wilden S; Kähler KC
PLoS One; 2018; 13(5):e0197780. PubMed ID: 29795621
[TBL] [Abstract][Full Text] [Related]
36. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
37. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
King JT; Tsevat J; Lave JR; Roberts MS
Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
[TBL] [Abstract][Full Text] [Related]
38. Dermatology life quality index in Thai patients with systemic sclerosis: a cross-sectional study.
Chularojanamontri L; Sethabutra P; Kulthanan K; Manapajon A
Indian J Dermatol Venereol Leprol; 2011; 77(6):683-7. PubMed ID: 22016275
[TBL] [Abstract][Full Text] [Related]
39. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre.
Kostopoulou P; Jouary T; Quintard B; Ezzedine K; Marques S; Boutchnei S; Taieb A
Br J Dermatol; 2009 Jul; 161(1):128-33. PubMed ID: 19298280
[TBL] [Abstract][Full Text] [Related]
40. Comorbidities, quality of life and patients' willingness to pay for a cure for type 2 diabetes in Taiwan.
Chang K
Public Health; 2010 May; 124(5):284-94. PubMed ID: 20546817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
